September 17, 2008

Oramed Pharmaceuticals Launches Preclinical Trials of Diabetes Drug

Oramed Pharmaceuticals, a developer of oral drug delivery systems, has launched preclinical trials of ORMD 0901, a GLP1-analog.

Oramed plans to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008. Oramed plans to launch Phase IIb trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009.

ORMD 0901 belongs to the incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.

Nadav Kidron, CEO of Oramed, said: "The launch of preclinical trials of ORMD 0901 and expansion of Oramed's platform marks the next strategic milestone for our company as we demonstrate the effectiveness of our oral delivery technology in yet another important family of polypeptide drugs for diabetes, that are until now only available in injection form."